摘要
目的探讨转录因子激活增强子结合蛋白4(TFAP 4)在肝细胞癌(HCC)中的表达及其与患者预后的关系。方法标本来源于2007年12月至2014年12月中山大学肿瘤防治中心的116例术后病理检查确诊为HCC患者。患者均签署知情同意书,符合医学伦理学规定。其中男103例,女13例;年龄22～75岁,中位年龄44岁。免疫组化法检测HCC组织TFAP 4的表达量,TFAP 4蛋白表达与临床病理参数之间的关系分析采用χ~2检验。生存分析采用Kaplan-Meier曲线和Log-rank检验。Cox比例风险回归模型分析TFAP 4在HCC组织中的表达与预后的关系。结果 TFAP 4高表达者54例,低表达者62例,其表达与患者临床病理参数无相关性(P>0.05)。TFAP 4高表达患者的无瘤生存和总体生存均更差(χ~2=11.030,4.269;P<0.05)。Cox回归分析显示,HBsAg阳性是影响HCC患者无瘤生存的独立危险因素(HR=4.722,95%CI:1.469～19.446,P<0.05),而TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素(HR=2.437,2.598;95%CI:1.352～4.394,1.036～6.515;P<0.05)。结论 TFAP 4高表达是影响HCC患者无瘤生存和总体生存的独立危险因素,TFAP 4高表达患者预后较差。TFAP 4可作为判断HCC患者预后的生物学标志物。
Objective To investigate the expression of transcription factor activating enhancerbinding protein 4(TFAP 4)in hepatocellular carcinoma(HCC)and its relationship with the clinical prognosis of HCC patients.Methods The tissue specimens were obtained from 116 HCC patients diagnosed by pathological examination in Sun Yat-sen University Cancer Center from December 2007 to December 2014.The informed consents of all patients were obtained and the local ethical committee approval was received.Among 116 patients,103 were male and 13 were female,aged 22-75 years with a median age of 44 years.The expression of TFAP 4 in HCC tissues was measured by immunohistochemical staining.The relationship between the expression of TFAP 4 protein and clinicopathological parameters was analyzed by Chi-square test.The survival analysis was conducted by Kaplan-Meier survival curve and Log-rank test.The relationship between TFAP 4 expression and clinical prognosis of HCC patients was analyzed by Cox's proportional hazards model.Results TFAP 4 was highly expressed in 54 patients and lowly expressed in 62.The expression of TFAP 4 was not associated with clinicopathological features(P >0.05).The tumorfree survival and overall survival of patients with high expression of TFAP 4 were worse than those with low expression of TFAP 4(χ2=11.030,4.269;P<0.05).Cox's regression analysis demonstrated that positive HBsAg was an independent risk factor for the tumor-free survival of HCC patients(HR=4.722,95%CI:1.469-19.446,P<0.05),whereas high expression of TFAP 4 was an independent risk factor for tumor-free survival and overall survival of HCC patients(HR=2.437,2.598;95%CI:1.352-4.394,1.036-6.515;P<0.05).Conclusions High expression of TFAP 4 is an independent risk factor for tumor-free survival and overall survival of HCC patients.Patients with high expression of TFAP 4 have poorer clinical prognosis.TFAP 4 can be used as a biomarker to predict the clinical prognosis of HCC patients.
作者
黄涛
沈露俊
陈奇峰
李旺
吴沛宏
Huang Tao;Shen Lujun;Chen Qifeng;Li Wang;Wu Peihong(Department of Minimally Invasive Intervention,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)
出处
《中华肝脏外科手术学电子杂志》
CAS
2019年第1期72-75,共4页
Chinese Journal of Hepatic Surgery(Electronic Edition)
基金
广东省公益研究与能力建设专项资金项目(2014A020212532)
关键词
癌
肝细胞
TFAP4
预后
免疫组织化学
Carcinoma,hepatocellular
TFAP4
Prognosis
Immunohistochemistry
